JOP20230295A1 - المركبات والطرق التي تستهدف الإبيريجولين - Google Patents

المركبات والطرق التي تستهدف الإبيريجولين

Info

Publication number
JOP20230295A1
JOP20230295A1 JOJO/P/2023/0295A JOP20230295A JOP20230295A1 JO P20230295 A1 JOP20230295 A1 JO P20230295A1 JO P20230295 A JOP20230295 A JO P20230295A JO P20230295 A1 JOP20230295 A1 JO P20230295A1
Authority
JO
Jordan
Prior art keywords
epigolin
roads
vehicles
target
pain
Prior art date
Application number
JOJO/P/2023/0295A
Other languages
English (en)
Inventor
Jeffrey Streetman Boyles
Michael Parvin Johnson
Daniel Scott Girard
Shannon Marie Harlan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of JOP20230295A1 publication Critical patent/JOP20230295A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

يتعلق الاختراع الحالي بالأجسام المضادة للإبيريجولين والتركيبات التي تشتمل عليها وطرق تصنيع و/أو استخدام الأجسام المضادة و/أو تركيبتها لعلاج اضطرابات الألم المزمن مثل ألم التهاب المفاصل العظمي أو ألم الاعتلال العصبي المحيطي السكري أو ألم أسفل الظهر المزمن.--
JOJO/P/2023/0295A 2021-05-21 2023-11-19 المركبات والطرق التي تستهدف الإبيريجولين JOP20230295A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163191496P 2021-05-21 2021-05-21
PCT/US2022/030058 WO2022246078A1 (en) 2021-05-21 2022-05-19 Compounds and methods targeting epiregulin

Publications (1)

Publication Number Publication Date
JOP20230295A1 true JOP20230295A1 (ar) 2023-11-19

Family

ID=82100776

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0295A JOP20230295A1 (ar) 2021-05-21 2023-11-19 المركبات والطرق التي تستهدف الإبيريجولين

Country Status (20)

Country Link
US (2) US12600767B2 (ar)
EP (1) EP4341288A1 (ar)
JP (2) JP7696449B2 (ar)
KR (1) KR20240009488A (ar)
CN (1) CN117440968A (ar)
AR (1) AR125902A1 (ar)
AU (1) AU2022277694A1 (ar)
BR (1) BR112023021829A2 (ar)
CA (1) CA3218753A1 (ar)
CL (1) CL2023003404A1 (ar)
CO (1) CO2023015694A2 (ar)
CR (1) CR20230538A (ar)
DO (1) DOP2023000253A (ar)
EC (1) ECSP23087684A (ar)
IL (1) IL308533A (ar)
JO (1) JOP20230295A1 (ar)
MX (1) MX2023013718A (ar)
PE (1) PE20240416A1 (ar)
TW (1) TWI859538B (ar)
WO (1) WO2022246078A1 (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI807338B (zh) * 2020-06-26 2023-07-01 美商美國禮來大藥廠 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009776A2 (en) 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. TREATMENT OF TNFα RELATED DISORDERS
RU2312109C2 (ru) 2003-03-14 2007-12-10 Тайсо Фармасьютикал Ко., Лтд. Моноклональное антитело и продуцирующая его гибридома
CN100512806C (zh) 2003-04-14 2009-07-15 Lts勒曼治疗系统股份公司 具有包含辣椒碱的聚硅氧烷基质的治疗贴剂
AU2005232657B2 (en) * 2004-04-08 2010-12-16 David B. Agus ErbB antagonists for pain therapy
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
AR085484A1 (es) 2011-04-06 2013-10-02 Lilly Co Eli ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA
TWI593705B (zh) * 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
CA2891855A1 (en) * 2012-12-21 2014-06-26 Sykehuset Sorlandet Hf Egfr targeted therapy of neurological disorders and pain
MX2015017852A (es) 2013-06-24 2016-08-11 Chugai Pharmaceutical Co Ltd Agente terapeutico que comprende el anticuerpo anti-epirregulina humanizado con ingrediente activo contra el carcinoma de pulmon de celulas no pequeñas excluyendo el adenocarcinoma.
EP3978525A1 (en) 2015-06-29 2022-04-06 Ventana Medical Systems, Inc. Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
JP2019202936A (ja) 2016-08-17 2019-11-28 中外製薬株式会社 抗Ｅｐｉｒｅｇｕｌｉｎ抗体と抗ＥＧＦＲ抗体との併用医薬
TWI807338B (zh) 2020-06-26 2023-07-01 美商美國禮來大藥廠 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途

Also Published As

Publication number Publication date
AU2022277694A1 (en) 2023-11-30
DOP2023000253A (es) 2023-12-29
IL308533A (en) 2024-01-01
AU2022277694A9 (en) 2023-12-07
US20250101091A1 (en) 2025-03-27
PE20240416A1 (es) 2024-03-05
CN117440968A (zh) 2024-01-23
EP4341288A1 (en) 2024-03-27
JP2025134758A (ja) 2025-09-17
CR20230538A (es) 2023-12-11
KR20240009488A (ko) 2024-01-22
CA3218753A1 (en) 2022-11-24
ECSP23087684A (es) 2023-12-29
WO2022246078A1 (en) 2022-11-24
US12600767B2 (en) 2026-04-14
JP2024522071A (ja) 2024-06-11
MX2023013718A (es) 2024-01-16
JP7696449B2 (ja) 2025-06-20
BR112023021829A2 (pt) 2023-12-19
TW202313680A (zh) 2023-04-01
CO2023015694A2 (es) 2023-11-30
TWI859538B (zh) 2024-10-21
AR125902A1 (es) 2023-08-23
CL2023003404A1 (es) 2024-06-21
US20220372124A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
MX2020013804A (es) Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos.
WO2021227307A8 (zh) 抗cd73抗体及其用途
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
SA520420801B1 (ar) أil جسام مضادة لـ -11
EA202092907A1 (ru) Мультиспецифические связывающие белки и их усовершенствования
WO2018069500A3 (en) Anti-lag-3 antibodies and compositions
EA201992131A1 (ru) Высокоаффинные специфичные к mage-a1 tcr и их применение
MX2022002682A (es) Anticuerpos anti-cd73.
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
EA202090372A1 (ru) Универсальные соединения авт и их применение
JOP20170170B1 (ar) صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
EA201992350A1 (ru) Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3
JOP20190187A1 (ar) مترافقات عقار جسم مضاد لـ ccr7
EA202091747A1 (ru) Составы антитела b7-h4
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
CR20220656A (es) Unión de anticuerpos multiespecíficos a bcma
MX2022014925A (es) Moduladores de il-17a.
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
MA43717B1 (fr) Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci
MX2021013602A (es) Inhibidores de jak.
EA202192008A1 (ru) Lilrb3-связывающие молекулы и варианты их применения
EA202192488A1 (ru) Антитела против tsg-6 и их применения